Business Insider
February 25, 2025 at 08:04 PM
Hims & Hers stock fell 27% as it plans to stop selling compounded weight loss drugs. The FDA removed semaglutide from its shortage list, affecting Hims & Hers' sales strategy. Hims & Hers' revenue grew 69% in 2024, with GLP-1 drugs representing about 20% of its sales. 👉 https://trib.al/Yy9JkDV
👍
❤️
😮
🙏
🇵🇸
😢
🇮🇱
✝️
🇪🇬
🇵🇬
52